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Abstract  
Background: Major psychiatric disorders have significant contributions to the global burden of disease. The 
pharmacological management of major psychiatric disorders is mainly challenged by patients’ lack of adherence to 
their medication. Although it may be well studied in the developed world, it is not well documented in less developed 
countries, including Ethiopia. Therefore, the aim of this study was to assess the prevalence of psychotropic medication 
non-adherence and its associated factors among psychiatric patients at two selected hospitals in eastern Ethiopia. 
Methods: A hospital-based cross-sectional quantitative study was conducted at Hiwot Fana Specialized University 
Hospital and Dil Chora Hospital from May to June, 2015.  A systematic sampling method was applied to recruit 660 
adult patients (18 years and older) with major psychiatric disorders at two selected hospitals in the eastern Ethiopia. 
The patients’ psychotropic medication non-adherence, attitude towards medication, perceived stigma and social 
support were assessed using adapted tools. Collected data were entered into EpiData version 3.5.3 and then exported 
to Statistical Package for social sciences (SPSS) version 20.0 for analysis. Descriptive and logistic regression analysis 
were carried out. Statistical association was declared using adjusted odds ratio (AOR) at 95% confidence interval (CI) 
and p< 0.05. 
Results: The prevalence of psychotropic medication non-adherence was 61.2% (95% CI: 57.3-65.0%). Being female 
(AOR=2.3; 95% CI: 1.4-3.8); taking low potency typical antipsychotic with antidepressants concomitantly (AOR=2.7; 
95% CI:1.0-6.9); being on treatment from 6 to 24 months (AOR=2.3; 95% CI:1.4,3.8); more than 24 months 
(AOR=2.5; 95% CI:1.5-4.1); substance use (AOR=2.6; 95% CI;1.7-4.0); perceived stigma (AOR=2.2; 95% CI:1.5-
3.1); patient’s poor attitude towards the medication (AOR=3.0; 95%CI:1.8-5.1), and poor social support (AOR=1.8; 
95%CI:1.3-2.7) were the factors  associated with psychotropic medications non-adherence. 
Conclusion: About two-third of the major psychiatric patients were non-adherent to their psychotropic medication. 
The non-adherence was significantly associated with being female, low potency treatment and concurrently ill, long 
treatment duration, substance use, perceived stigma, poor attitude towards medications and lack of social support. 
Therefore, concerned stakeholders should focus on the associated factors in order to improve adherence to 
psychotropic medication.  
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Introduction  
Globally, psychiatric disorders affect approximately 
450 million people (WHO, 2008). The psychiatric 
disorders have caused 31.7% of different long-term 
disabilities and dependency. The major contributors to 
the long-term disability and dependency are unipolar 
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depression (11.8%), alcohol-use disorders (3.3%), 
schizophrenia (2.8%), bipolar depression (2.4%) and 
dementia (1.6%) (Mathers and Loncar, 2006). The 
World Health Organization (WHO) has defined 
medication non-adherence “as a case in which a 
person’s behavior in taking medication does not 
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corresponds with agreed recommendations from a health 
care provider. It can be either willful or inadvertent 
which can include failing to initially fill or refill a 
prescription, discontinuing a medication before the 
course of therapy is completed, taking inappropriate 
dose of the medication than prescribed and at the 
wrong time” (WHO, 2003).  
Patients who are suffering from major psychiatric dis-
orders are less likely to adhere to their treatment 
(Rekha et al., 2005; Fawad et al., 2008). Patients having 
poor reasoning skills, misbehaving towards prescribed 
medications and having poor insight about their illness 
and medication are some of the risk factor for psychotropic 
medication non-adherence (Colom and Vieta, 2002;Al-
Qasem, 2011). Furthermore, patients who are non-ad-
herent to their medication cause a complex problem 
for health care service, as a result of recurrent relapse 
of symptoms; become less responsive to subsequent 
medication; poorer mental and physical functioning; 
increase substance abuse and suicidal behavior; com-
plications in co-morbid medical conditions; psychiatric 
hospitalization and health care costs (Lindstrom and 
Bingefors, 2000; Colom and Vieta, 2002; Lacro, 2002; 
Burton, 2007; Al-Qasem, 2011).  
Information about the level of major psychiatric disorders 
patients’ medication non-adherence and its associated 
factors is essential to inform policymakers and other 
concerned stakeholders. Hence, identifying the factors 
associated with psychotropic medication non-adherence 
is the foremost step to address the root causes and 
minimize unintended consequences of psychotropic 
medication non-adherence. Although some studies 
have been conducted in Ethiopia, we could not find a 
study in Eastern part of Ethiopia during our literature 
reviews. Therefore, this study aimed to assess the 
prevalence of psychotropic medication nonadherence 
and its associated factors among adult major psychiatric 
disorder patients on treatment follow up at two clinics 
at Hiwot Fana Specialized University Hospital (HFSUH) 
and Dil-Chora Hospital (DCH) in the Eastern selected 
psychiatric Ethiopia.  
Materials and methods 
Study design and settings  
A hospital-based cross-sectional quantitative study 
was conducted to assess psychotropic medication non-
adherence and its associated factors at HFSUH and 
DCH from 1 May to June, 2015. The two hospitals were 
selected purposefully due to having psychiatric clinics 
with an admission center and also used as referral 
destinations in the eastern Ethiopia.The HFSUH is a 
teaching hospital of Haramaya University College of 
Health and Medical Sciences. The hospital is in Harar 
city and 526km to the east of Addis Ababa. Similarly, 
DCH is found in Dire Dawa administration and is 
515km to the east of Addis Ababa. In the two psychiatric 
clinics, there were 1,942 patients with major psychiatric 
disorders.  
Sample size determination and sampling 
procedure  
The sample size was calculated using a single population 
proportion formula considering 50% proportion for 
non-adherence to the psychotropic medications, 4% of 
margin of error and 95% significance level. Then, 10% 
of the sample size was added for methodological non-
response. Then sample size (n=660) was proportionally 
allocated to size of psychiatric patients who had 
follow-up at HFSUH and DCH psychiatric clinics.  
Finally, 660 (462 from HFSUH and 198 from DCH) 
patients were interviewed and their documents (patients 
card) were reviewed. A systematic sampling method 
was applied to select 660 study participants. Here, the 
sampling frame was constructed based on the patients’ 
identification card numbers, which were obtained 
from the psychiatric patients’ registry. Then the study 
participants were selected every other patient (kth =2). 
The first patient was selected randomly and the others 
were selected systematically based on the ‘kth’ value. 
In the case of a patient who had re-visit or consultation 
during the study period, the patient’s identification 
number was cross-checked against the constructed 
sampling frame (list), and duplicated studies were 
excluded to avoid re-interview as well as document re-
review. The upcoming psychiatric patients were 
consider for the sampling and continued every other 
patients. In the meantime, detail explanation about the 
aim of the study was provided to the study participants 
to achieve a desired response rate. The detail of 
participant’s recruitment process have illustrated 
schematically (Fig. 1).  
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 Figure 1: Schematic presentation of participant recruitment process. 
Population  
Patients with major psychiatric disorders (schizophrenia, 
bipolar and major depressive disorders) and who were 
on psychotropic medication were eligible to the study. 
Those patients who had had more than one visit that 
was confirmed from the patients record (registry) and 
patient aged 18 and above years (based on the record 
from patient card) were included in the study. Unfor-
tunately, patients who were acutely agitated or se-
verely retarded; and unable to communicate with the 
data collectors, and who had re-visited or already included 
previously were excluded from the study. 
Data collection method 
Data were collected using adapted structured question-
naire that comprised of patients’ socio-demographic 
characteristics, health-care-related factors, patient re-
lated factors and other variables (Hogan et al., 1983; 
Morisky et al., 2008; Dalgard, 2009; Mahaye et al., 
2012; Abiola et al., 2013). This study focused on three 
major psychiatric disorders (schizophrenia, bipolar 
disorders and major depressive disorders). Both primary 
and secondary data were taken from psychiatric patients 
and patient records (registry), respectively. Initially, 
primary data were collected from the study participants, 
and then secondary data (document reviews) were carried 
out. Data on the type of major psychiatric disorder 
diagnosis and of medication, co-morbidities (if any), 
the group of drug(s), frequency of drug taken and other 
related variables found in the patient record were taken 
through document or record review.. 
 
Data on the patients’ level of medication adherence, 
attitude towards their medication, social/family sup-
port, and their perceived stigma were collected using 
faceto-face interview with the patients, and eventually 
rated according to the adopted standard. Medication 
adherence and the associated factors were assessed us-
ing standard measurements such as Morisky Medica-
tion Adherence Rating Scale (MMARS); Drug Inven-
tory Attitude (DIA) score; Oslo 3-items Social Support 
Scale (OSS-3) and perceived stigma 
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evaluation tools. Psychotropic medication non-adherence 
was assessed using the eight items Morisky Medication 
Adherence Rating Scale (MMARS) (Morisky et al., 
2008; Mahaye et al., 2012). Each item on the MMARS 
was used to assess the patient’s medication taking 
behavior, and presented dichotomously (yes=0, no=1), 
in which score “1” is corresponding to negative 
answers. The sum of the MMARS score was greater 
than or equal to three negative answers. It was 
considered as non-adherent. On the other hand, the 
patients’ attitude towards medication was assessed by 
ten items of the DIA. The DIA score less than six was 
considered negative attitude towards medication 
(Hogan et al., 1983). Furthermore, social support was 
assessed using the Oslo 3-items of OSS-3. It was 
described as the number of people that the person felt 
close to, interest and concern shown by others, and the 
ease of obtaining practical help from others. The sum 
score scale ranged from 3 to 14; in which 3 to 8 stands 
for “poor social support” and 9 to 14 stands for “good 
support” (Dalgard, 2009; Abiola et al., 2013). In addition, 
perceived stigma was measured using the 3-items’ 
perceived stigma measuring scale. Perceived stigma 
with an overall possible score ranging from 0 (no 
perceived stigma) that has at least one ‘yes’ perceived 
stigma to 3 (maximally perceived stigma).  
Data quality control 
 Prior to data collection, a two-day training was given 
to the data collectors and the supervisors about the 
sampling procedure, content of the questionnaire, 
interview techniques, consent taking and confidentiality. 
Pretest was made in the nearby health facility (Harar 
Jugol Hospital) to make necessary modification on the 
data collection tools, sampling procedures and interview 
methods. Data were collected by six psychiatric nurses 
through face-to-face interview method and record 
review. Close supervision was held on the data 
collection process by two supervisors who had Master 
of Science degree in integrated clinical and community 
mental health. Eventually, the collected data were 
checked for completeness and consistency, coded and 
entered to computer based software for cleaning. Re-
coding of the variables were carried out accordingly to 
suit with statistical methods.  
 
 
 
Data processing and analysis 
The collected data were entered into Epidata (3.5.3) 
and then exported to SPSS (20.0) for analysis. Descrip-
tive statistics was used to compute frequencies, percent-
age, mean and standard deviation. Bivariate analysis 
was carried out for crude odds ratio (COR). Hosmer-
Lemshow goodness-of-fit was used to construct the final 
model. The variables that had a P-values less than 0.25 
in the binary logistic regression were included in the 
multiple logistic regression analysis. The multiple lo-
gistic regression analysis was computed to control con-
founders and to determine the independent predictors of 
psychotropic medication non-adherence using AOR at 
95% CI and P-Value less than 0.05. 
Ethical consideration  
Ethical approval was obtained from Institutional 
Health Research Ethical Review Committee of the 
College of Health and Medical Science at Haramaya 
University. Permission and letter of cooperation was 
presented to the health institutions’ administrative 
bodies. Participation was on voluntary basis and 
participants were informed that they had full right to 
skip, interrupt or withdraw at any time during the 
interview process if they fill uncomfortable. Informed 
consent was obtained mainly from study participants, 
but care givers and or relatives were asked for their 
willingness to interview their relative as necessary. 
Results 
Socio-demographic characteristics 
A total of 613 participants were interviewed with a 
response rate of 92.9% (613/660) (Fig. 1). Of these 
study participants, 76.1% were males, and 56.2% were 
urban dwellers. The mean (SD) age of the participants 
was 32.9(±10.7) years (Table 1). 
Prevalence of psychotropic medication non-
adherence 
The study participants by their diagnosis were schizo-
phrenia (69.2%), major depressive disorder (21.5%) 
and bipolar-disorder (5%) respectively. The overall 
prevalence of psychotropic medication non-adherence 
among the patients with major psychiatric disorders 
was 61.2% (95% CI: 57.3-65.0%). Of these, the prev-
alence of medication non-adherence among the patients 
with schizophrenia, major depressive disorder and 
bipolar I disorder were 60.9%, 62.9% and 58.9% 
respectively (Fig. 2). 
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Table1: Sociodemographic characteristic of study 
participants at two selected hospitals in eastern 
Ethiopia from May-June, 2015 (n=613). 
*religion (others): Catholic=2 and Wakifata =1; Ethnicity (other): 
1Arigoba and Silte   
Patients self-reported reasons for psychotropic 
medication non-adherence  
In this study, patients’ skipping of medications (58.1%), 
fear of side-effects (69.0%), lack of information about 
their illness (54.8%), lack of information about their 
medication (56.3%), poor social support (50.1%), had 
perceived stigma (53.7%) and had history of different 
substance abuse (58.3%) were the most common 
reasons for psychotropic medication non-adherence  
(Table 2).  
 
Clinical factors for medication non-adherence  
The non-adherence for each prescribed treatment was 
higher than the total adherence level. However, some 
of the cell are with very few count, and also some 
common drugs were prescribed for different type of 
psychiatric disorders (Table 3). 
 
Figure 2: Psychotropic medication non-adherence among 
major psychiatric disorders at two selected hospitals in 
eastern Ethiopia from May-June, 2015 (n= 613). 
Factors associated with psychotropic medication 
non-adherence 
On the bivariate analysis, sex, residence, antipsychotic 
drug taken with antidepressants concomitantly, side 
effect, cost of the medication, duration of treatment, 
history of substance use, patient’s attitude towards the 
medication, social support and perceived stigma with 
P-value less than 0.25 were entered in to multivariate 
analysis. In multivariate analysis being female (AOR 
=2.3; 95% I: 1.4-3.8); taking low potency typical anti-
psychotic medication concomitantly with antidepressants 
(AOR=2.7; 95% CI: 1.0-6.9); being on treatment for 624 
months (AOR=2.3; 95% CI:1.4-3.8); being on treatment 
for >24 months (AOR=2.5, 95% CI: 1.5-4.1); substance 
use (AOR =2.6; 95% CI:1.7-4.0); perceived stigma 
(AOR =2.2; 95% CI:1.5- 3.1); patient attitude towards 
the drug (AOR=3.0; 95% CI: 1.8-5.1); and having  
poor social support (AOR=1. 8; 95% CI:1.3-2.7)  were 
significantly associated with medication non-adherence 
(Table 4). 
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Variables                                           Categories Freq. % 
Site  Dil Chora Hospital 181 29.5 
HFUH 432 70.4 
Sex Male 466 76.1 
Female 147 23.9 
Age  (years) 18-30   292 47.6 
31-45       198 32.3 
>45  123 20.1 
Marital status               Single 254 41.4 
Married  293 47.7 
Divorced  52 8.5 
Widowed 14 2.5 
Religion                         Orthodox  195 31.8 
Protestant 42 6.8 
Muslim   370 60.3 
Others  3 0.4 
Ethnicity                       Amhara 185 30.1 
Oromo 307 50.0 
 Harari  35 5.7 
Somali 23 3.7 
Tigray 24 3.9 
Gurage 37 6.0 
Others  2 0.3 
Occupation                    Government employed 93 15.1 
Private business 86 14.1 
Daily laborer 47 7.7 
Jobless 131 21.3 
Student 44 7.2 
Farmer  149 24.3 
House wife 62 10.1 
Educational 
status           
Unable to read and write 144 23.5 
Read and write  74 12.1 
Primary school  151 24.6 
Secondary school  140 22.8 
Diploma and above 103 16.8 
Monthly 
income (in 
birr)  
≤600 87 27.0 
601-1000   91 28.3 
1001-2000 85 26.4 
≥2000 59 18.3 
Residence                     Rural   268 43.6 
Urban 345 56.2 
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Table 2: Description of reasons reported by patients for their psychotropic medication non-adherence among major 
psychiatric disorder patients at two selected hospitals in eastern Ethiopia from May-June, 2015 (n=613). 
Variables  Categories  Freq. % 
Skipping overall skipping of medicine 356 58.1% 
skip related to forgetfulness 228 64.0% 
skip due to feeling better 81 22.8% 
skip due to fear of side-effect 54 15.2% 
Side-effect Mouth dryness, blurred vision and  constipation 149 69.0% 
drowsiness and sedation) 54 25.0% 
extra-pyramidal symptoms 31 14.4% 
Lack of 
information  
 about their  illness  136 22.1% 
about their medication 155 25.2 
Lack of support  Negative attitude toward medication  119 19.4% 
Poor social support  307 50.1% 
Perceived stigma  328 53.7% 
Substance   Overall substance use 357 58.3% 
Chew Khat 341 95.5% 
Ciggarate smoking  176 49.3% 
alcohol drinking 24 6.7% 
other substances use 6 1.7% 
Cost of drug drug not free (with payment) 492 80.3% 
Note that: other substances: shisha, homemade beverages  
(613) multiple response was possible 
Discussion  
This study determined the prevalence of psychotropic 
medication non-adherence among the patients with 
major psychiatric disorders in Eastern Ethiopia, and it 
was 61.2%. The most frequently raised reasons for 
their psychotropic medication non-adherence were the 
patients’ skipping their medication, fear of side-effects, 
lack of information about their illness and their medi-
cation, poor social support, having perceived stigma and 
having a habit of substance. Furthermore, the factors 
significantly associated with psychotropic medication 
non-adherence were being female, taking low potency 
typical antipsychotic with antidepressants concomitantly, 
medication side-effects, treatment duration longer than six 
months, substance use, patients’ attitude towards the 
medication, poor social support and having perceived 
stigma were significantly associated with non-adherence. 
 
The present finding indicated, psychotropic medication 
non-adherence was 61.2% (95% CI: 57.3-65.0%). 
This study finding is quite greater than the studies con-
ducted in Denmark, Pakistan, India, Nigeria, Kenya, 
South Africa and Ethiopia (Hansen et al., 2004; Okonji 
et al., 2005; Fawad et al., 2008; Kazadi et al., 2008; 
Adegoke et al., 2011; Sangeeta et al., 2012; Sharma et 
al., 2012; Kenfe et al., 2013; Ibrahim et al 2015a, b) 
which have showed that non-adherence ranged from 
33.5% to 55.6%. The difference might be due to high 
substance use in our study area, where 58.3% of the 
study participants were using substance. This is also 
confirmed from the inferential analysis which have 
showed that patients who have had psychostimulant or 
addictive substance use were approximately three 
times more likely to be non-adherent to their medication 
than non-users. This study finding is consistent with 
the studies conducted in different areas (Hudson et al., 
2004; Janssen et al 2006; David et al., 2012; Markowitz et 
al., 2013; Tefera et al., 2013). 
 
The female patients with major psychiatric disorders 
were two times more likely to be non-adherent to their 
medication than the male patients. This is in line with 
a study done in India (Banerjee, 2012). In addition, 
major psychiatric patients who were taking low 
potency typical antipsychotic with antidepressants 
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Table 3: Major psychiatric disorders patients’ treatment related factors at two selected hospitals in eastern Ethiopia 
from May-June, 2015 (n=613). 
 
concomitantly were three times more likely to be non-
adherent than those patients who were taking atypical 
antipsychotics with antidepressants. This finding is 
consistent with other study reported that the presence 
of side effects of the medication was associated non 
adherence (Lambert et al., 2004). Likewise, patients 
who were on treatment from 6- 24 months and > 24 
months were two times  more likely to be non-adherent 
than those who were on treatment for less than six 
months. This finding is consistent with the treatment 
recommendations guideline of the national institute 
for health (NIH, 2009).  
 The present study finding showed that 50.1% of the 
patients with major psychiatric disorders had poor 
social support. This finding is quite lower than the 
findings from different studies conducted in Ethiopia 
(84.6%) (Kenfe et al., 2013), India Kolkata (66.9%) 
(Banerjee, 2012), Sudan (64.0%) (SAP, 2010) and 
Thailand (77.0%) (Prukkanone et al., 2005). The 
difference might be related to sociocultural contexts in 
which people in the eastern Ethiopia are so interactive 
and well supportive to their neighbors and other people 
regardless of their medical or other conditions. Likewise, 
patients who had poor social support were about two 
times more likely to be non-adherent to their medication 
than the patients who had good social support (AOR 
1.8, 95%CI:1.3-2.7). This fining is similar with other 
studies that indicated social support serving as a cue to 
action or reinforcing factor for psychiatric patient’s 
medication adherence (Adegoke et al., 2011; Scheurer 
et al., 2012; Kenfe et al., 2013; Ibrahim et al., 2015a). 
The present finding have showed that patients who had 
perceived stigma were two times more likely to be 
non-adherent than the patients who had no perceived 
stigma. 
Variables                                            Categories   Freq.                                        %
Type of major psychiatric disorders                   
 
Major depressive disorder 132 21.5 
Schizophrenia   425 69.2 
Bipolar I disorder 56 9.1 
Class of anti-depressant taken          Tricyclic anti-depressants  65 43 
selective serotonin reuptake inhibitors 86 57 
Type of antipsychotic taken with 
antidepressants  
Typical low potent&  39 39 
Typical high potent  49 49 
Atypical antipsychotics     12 12 
antipsychotic medication(s) that the 
patient currently taking 
Typical low potent &  320 71.7 
Typical high potent  82 18.4 
Atypical antipsychotics   44 9.9 
Mood stabilizer medication Sodium valproate 37 58.7 
Carbamazepine  26 41.3 
Co- morbidity a                          Yes         34 5.5 
No        579 94.5 
Side effect                 
 
Yes   216 35.3 
No     397 64.7 
Duration of treatment                ≤6months     146 24 
7-24  months 231 38 
>24 months   231 38 
Experiencing skipping of medication Yes  356 58.1 
No  257 49.9 
*Atypical antipsychotics (AAP): Also known as second generation antipsychotics (SGAs)) are a group of antipsychotic drugs 
(antipsychotic drugs in general are also known as major tranquilizers and neuroleptics. 
*Typical antipsychotics are a class of antipsychotic drugs first developed in the 1950s and used to treat psychosis. Typical 
antipsychotics may also be used for the treatment of acute mania, agitation, and other conditions. 
*Typical high-potent: are antipsychotic drugs have been formulated as the decanoate ester (e.g. fluphenazine decanoate) to 
allow for a slow release of the active drug when given as a deep, intramuscular injection. 
& Typical low potent: are  antipsychotic drugs with low-potency antipsychotics which is requiring higher doses to achieve 
the same effect as high-potency ones, but with different side effects 
a Co-morbidities:  is the presence of one or more medical/surgical/neurological/other mental illness in addition to major 
psychiatric disorders. 
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Table 4: Predictors of psychotropic medication non-adherence among major psychiatric disorders patients at two 
selected hospitals in eastern Ethiopia from May-June, 2015 (n= 613) 
Variables 
 
Categories 
  
Medication non-adherence COR (95% CI) AOR (95% CI) 
Yes (%) No (%) 
Sex Male  272(58.4) 194(41.6) 1 1 
Female   103(70.1) 44(29.9) 1.7(1.2-2.5) 2.3(1.4-3.8)* 
Residence Rural  150(56.0) 118(44.0) 1 1 
Urban  225(65.2) 120(34.8) 1.5(1.1-2.1) 0.8(0.3-2.5) 
antipsychotics   taken  with 
anti-depressants 
Typical  30(76.9) 9(23.1) 2.5(1.01-6.1) 2.7(1.0-6.9) 
Atypical               35(57.4) 26(42.6) 1 1 
Side-effect                 Yes  161(74.5) 55(25.5) 2.5(1.7-3.6) 2.3(1.5-3.4)* 
 No                                        214(53.9) 183(46.1) 1 1 
Anticholinergic side-effect Yes  113(75.8) 36(24.2) 2.4(1.6-3.7) 2.2(1.4-3.4)* 
No  262(56.5) 202(43.5) 1 1 
Sleep related side-effect Yes  46(85.2) 8(14.8) 4.0(1.9-8.7) 2.4(1.1-5.4)* 
No  329(59.8) 230(41.2) 1 1 
Duration of treatment             ≤6months 67(45.9) 79(54.1) 1 1 
7-24months 150(64.9) 81(35.1) 2.2(1.4-3.3) 2.3(1.4-3.8)* 
≥25months 155(67.1) 76(32.9) 2.4(1.6-3.7) 2.5(1.5-4.1)* 
Cos of treatment                              Freely   85(70.2) 36(39.8) 1.7(1.1-2.5) 0.8(0.5-1.4) 
Paid   290(58.9) 202(41.1) 1 1 
Substance use Yes  244(68.3) 113(31.7) 2.1(1.5-2.9) 2.6(1.7-4.0)* 
No  131(51.2) 125(48.8) 1 1 
Khat use Yes  232(68.0) 109(32.0) 1.9(1.4-2.7) 1.5(1.0-2.1) 
No  143(52.6) 129(47.4) 1 1 
Cigarette smoking Yes  133(75.6) 43(24.4) 2.5(1.7-3.7) 1.9(1.2,2.9)* 
No  242(55.4) 195(46.6) 1 1 
Alcohol drinking Yes  21(87.5) 3(12.5) 4.7(1.4-15.8) 2.5(0.7-8.9) 
No  354(60.1) 235(39.9) 1 1 
Attitudes towards the drug Negative              96(80.7) 23(19.3) 3.2(1.9-5.2) 3.0(1.8-5.1)* 
Positive 279(56.5) 215(43.5) 1 1 
Social support Poor  212(69.1) 95(30.9) 2.0(1.4-2.3) 1.8(1.3-2.7)* 
Good  163(53.3) 143(46.7) 1 1 
Perceived stigma  Yes  240(73.2) 88(26.8) 3.1(2.2-4.3) 2.3(1.5-3.1)* 
No   133(47.0) 150(53.0) 1 1 
Note that: * indicate significant association at 95% confidence interval; COR: Crude odd ratio; AOR: adjusted odds ratio  
  
 
This finding is consistent with other studies’ finding 
(Sirey et al., 2001; Wing et al., 2002; Gabriel and 
Violato, 2010). Likewise, the odds of being among 
patients who had negative attitude towards their 
medication were three times more likely to be non-
adherent to their psychotropic medication than those 
who had positive attitude towards their medication. 
This is also supported by different studies (Hogan et 
al., 1983; Sirey et al., 2001; Acosta et al., 2012).  
Strength and limitations of the study 
This study used standard adapted measurement tools 
to assess psychotropic medication non-adherence, attitudes 
towards their medication, social support and perceived 
stigma. We used comprehensive data acquisition methods 
(face-to-face-interview and document/record reviews). 
Different quality assurance measures, probability sampling 
method and inferential statistical methods were applied to 
control confounders and maintain the credibility of the 
finding. Although we applied different measures and 
approaches to assure the quality of findings, this study 
have also some limitations. This study used only 
quantitative approach and patients and care givers 
perspectives were not addressed through exploratory 
study. So this might tends to underestimate the medication 
non-adherence due to recall bias. This hospital-based 
cross-sectional study design might not establish cause 
and effect relationship as well as might not be shown 
the temporality effect on medication adherence. Furthermore, 
classification of the major psychiatric disorders are 
also problematic due to mixed nature or comorbidity 
and co-medication issues.   
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Conclusion 
About two-third of major psychiatric disorders pa-
tients found to be non-adherent to their psychotropic 
medication that associated with different reasons. 
Being female, taking low potency antipsychotic taken 
with anti-depressants concomitantly, side-effect, treat-
ment duration longer than six months, substance use, 
negative attitude towards the drug, poor social support 
and having perceived stigma were the factors signifi-
cantly associated with medication non-adherence. This 
study finding will give an insight to any concerned bodies 
about the level of major psychiatric patients’ medication 
non-adherence and associated factors. We suggest 
researchers should undertake further studies using 
analytical study design to establish causal relationships 
of psychotropic medication non-adherence and associated 
factors. 
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